INTEgRated Health CARE for Patients With Frailty and Heart Failure

Last updated: June 12, 2024
Sponsor: Vestre Viken Hospital Trust
Overall Status: Active - Recruiting

Phase

N/A

Condition

Hyponatremia

Chest Pain

Heart Failure

Treatment

INTERCARE-HF

Clinical Study ID

NCT06444321
678261
  • Ages > 18
  • All Genders

Study Summary

Frailty, an aging-related syndrome of physiological decline characterized by marked vulnerability to adverse health outcomes, has attracted increasing attention in cardiology due to the growing elderly population with heart failure. Frail patients are mainly excluded from large cardiovascular intervention studies, and clinical trials addressing frailty and showing an impact on treatment on symptom burden, quality of life and /or outcome has been requested in recent guidelines and consensus documents. The INTEgrRated health CARE for patients with severe frailty and Heart Failure (INTERCARE-HF) is a proof-of-concept study that aims to evaluate the effect of integrated healthcare services for heart failure patients with a severe level of frailty by establishing interdisciplinary and coordinated follow-up teams across the healthcare boundaries. These teams will assess the patient's needs, goals, and risk areas, conduct advance care planning, and develop individualized treatment and follow-up plans. An open-label, non-randomized intervention study aims to recruit 20 patients and heart failure and a clinical Frailty Score (CSF) >=5. A control-group (N=40) matched on age an clinical frailty scale score will be included. The overall hypothesis is that the intervention is feasible in routine clinical practice with favorable effects on quality of life, symptoms, caregiver distress, and healthcare service utilization.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age >18 years old

  • Admitted to hospital with heart failure with symptoms of decompensation includingdyspnoea in NYHA class ≥ II, pulmonary congestion on chest x-ray and/or other signslike oedema or positive rales on auscultation and elevated NT-proBNP concentrationsat screening

  • Clinical Frailty Score ≥5

  • Signed informed consent by patient and closest relatives* and expected cooperationaccording to the protocol, ICH/GCP and national/local regulations

  • Although we preferably will recruit both patients and their relatives,participation from the next-of-kin will not be an exclusion criterium.

Exclusion

Exclusion Criteria:

  • Inability to comply with all study requirements, due to major co-morbidities orpsychosocial issues, or a history of noncompliance, that might compromise thepatient's ability to understand and/or comply with the protocol instructions orfollow-up procedures.

  • Not being able to understand Norwegian.

  • Permanent nursing home and estimated to stay alive for less than 6 months

Study Design

Total Participants: 60
Treatment Group(s): 1
Primary Treatment: INTERCARE-HF
Phase:
Study Start date:
June 06, 2024
Estimated Completion Date:
December 20, 2028

Connect with a study center

  • Drammen Hospital

    Drammen, Viken 3004
    Norway

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.